Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …

Background The safety and immunogenicity profile of COVID-19 vaccines when administered
concomitantly with seasonal influenza vaccines have not yet been reported. We therefore …

… Marchevsky, 5 Moncy Mathew, 8 Andrea Mazzella, 8 Yama F. Mujadidi, 5 Lucia Parolini,
1 Claire Petersen, 3, 4 Emma Plested, 5 Katrina M. Pollock, 6 Thurkka Rajeswaran, 8 …

Background Older adults, particularly in long-term care facilities (LTCF), remain at considerable
risk from SARS-CoV-2. Data on the protective effect and mechanisms of hybrid immunity …

Background Invasive pulmonary aspergillosis is a complication of severe COVID-19, with
regional variation in reported incidence and mortality. We describe the incidence, risk factors …

Objective To assess how national antimicrobial susceptibility data used to inform national
action plans vary across surveillance platforms. Methods We identified available open-access, …

Materials and methods: We performed a retrospective analysis of all adult patients undergoing
a kidney transplant biopsy in 2015at a major teaching hospital in the UK as part of a …

We commend the recent comments from Undurraga and colleagues, which continue to
highlight challenges in antimicrobial resistance (AMR) in the Americas. 1 While the cost-…

A 30-year-old man with advanced HIV and disseminated histoplasmosis deteriorated after
stepping down from intravenous liposomal amphotericin B to itraconazole. Therapeutic levels …

Background Immunosuppressive therapies have become a cornerstone of the management
of severe COVID-19. The impact of these therapies on secondary infections and …